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Abstract
Background: Soluble fibers lower serum lipids, but are difficult to incorporate into products
acceptable to consumers. We investigated the physiological effects of a concentrated oat β-glucan
on cardiovascular disease (CVD) endpoints in human subjects. We also compared the
fermentability of concentrated oat β-glucan with inulin and guar gum in a model intestinal
fermentation system.
Methods: Seventy-five hypercholesterolemic men and women were randomly assigned to one of
two treatments: 6 grams/day concentrated oat β-glucan or 6 grams/day dextrose (control). Fasting
blood samples were collected at baseline, week 3, and week 6 and analyzed for total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, homocysteine and C-reactive
protein (CRP). To estimate colonic fermentability, 0.5 g concentrated oat β-glucan was incubated
in a batch model intestinal fermentation system, using human fecal inoculum to provide
representative microflora. Fecal donors were not involved with the β-glucan feeding trial. Inulin and
guar gum were also incubated in separate serum bottles for comparison.
Results: Oat β-glucan produced significant reduction from baseline in total cholesterol (-0.3 ± 0.1
mmol/L) and LDL cholesterol (-0.3 ± 0.1 mmol/L), and the reduction in LDL cholesterol were
significantly greater than in the control group (p = 0.03). Concentrated oat β-glucan was a
fermentable fiber and produced total SCFA and acetate concentrations similar to inulin and guar
gum. Concentrated oat β-glucan produced the highest concentrations of butyrate at 4, 8, and 12
hours.
Conclusion: Six grams concentrated oat β-glucan per day for six weeks significantly reduced total
and LDL cholesterol in subjects with elevated cholesterol, and the LDL cholesterol reduction was
greater than the change in the control group. Based on a model intestinal fermentation, this oat β-
glucan was fermentable, producing higher amounts of butyrate than other fibers. Thus, a practical
dose of β-glucan can significantly lower serum lipids in a high-risk population and may improve
colon health.
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Background
Cardiovascular disease (CVD) remains the top cause of
death in the United States, with saturated fat and trans fat
intake, serum cholesterol, and obesity as major risk fac-
tors. Diets recommended for improvement of cardiovas-
cular risk factors include a diet high in dietary fiber. Cereal
fibers that are high in water-soluble fiber, such as β-glu-
can, may improve cardiovascular disease risk through
improvements in serum cholesterol and other intermedi-
ary risk factors. Oats are high in soluble fiber and appear
to reduce CVD risk when consumed as part of a moderate
fat, balanced diet. Soluble fiber β-glucan is thought to be
the active component for the cholesterol lowering effect of
oats. Few studies have been conducted on the effective-
ness of concentrated β-glucan from oats and changes in
physiological endpoints.
Concentrated  β-glucan from oat is now commercially
available as a dietary supplement. Oat β-glucan is a natu-
ral polymer comprised of individual glucose molecules
that are linked together by a series of β-(1–3) and β-(1–4)
linkages. Beta-glucan was identified as the major fer-
mentable component in both cooked and uncooked
rolled oats; the beta-glucan was not affected by cooking
[1]. Rolled oats and isolated beta-glucan (termed oat gum
in the report) contributed to increased gut viscosity in
male Wistar rats [2].
The hypothesis that soluble dietary fiber lowers blood
cholesterol levels by interfering with the absorption of
dietary cholesterol is appealing. Increased gut viscosity
may prevent dietary cholesterol from reaching the intesti-
nal epithelium. However, it is unlikely that fiber-induced
hypocholesterolemia is solely a result of this mechanism
[3]. Exogenenous cholesterol represents only about one
quarter of the body's cholesterol, and a significant change
in absorption would lead to even smaller changes in
blood cholesterol levels. Some fibers may decrease
absorption of dietary cholesterol by altering the composi-
tion of the bile acid pool. Pectin and oat bran increased
the portion of the total bile acid pool that was deoxycholic
acid (DCA) [4]. DCA has been noted to decrease the
absorption of exogenous cholesterol in humans [5]. Fer-
mentation products may also alter cholesterol metabo-
lism. Propionate is thought to suppress cholesterol
synthesis, but some results have been inconclusive [6-10].
Acetate produced by the fermentation of oat bran may
also contribute to cholesterol lowering [11].
Studying gut effects of fiber in humans is difficult due to
the invasive and expensive nature of colonic observation
as well as the dynamic nature of the colon. Excreted colon
contents will not necessary represent colon contents in the
proximal or even distal colon, due to continual fermenta-
tion of fiber and continual absorption of minerals and
SCFA across the epithelium. In vitro fermentation is a
noninvasive, time-efficient means to estimate fiber fer-
mentability.
The cholesterol lowering effect of whole oats has been
well documented and the United States FDA issued a
health claim on oats for the prevention of cardiovascular
disease in 1996 [12]. However, limited research has been
conducted with oat β-glucan separated from the oat grain.
This current paper aims to determine if the beneficial
physiological effects of oats can be seen with concentrated
oat β-glucan.
A barrier to use of soluble fiber in the past has been the
poor acceptability of foods high in soluble fiber for an
extended period. We measured the effect of 6 g/day of
concentrated β-glucan from oat on biomarkers of interest
in CHD and CVD. The human feeding trial was designed
to identify if the physiological effects of concentrated β
glucan from oat will improve serum biomarkers of cardi-
ovascular risk in subjects at high risk of cardiovascular dis-
ease by measuring changes in total cholesterol, LDL-
cholesterol, HDL-cholesterol, triglycerides, apolipopro-
tein A-1, apolipoprotein B and other blood metabolites.
Model intestinal fermentation was used to estimate in
vivo short-chain fatty acid production.
Methods
Ninety hypercholesterolemic subjects were recruited for
the study via flyers posted on the University of Minnesota
campus and newspaper advertisements in the University
of Minnesota Daily newspaper. To be included in the
study, subjects needed to be healthy, non-smoking men
and women between the ages of 22 and 65 years at risk for
CVD (as defined by a total cholesterol greater than 200
mg/dl), with spoken and written English literacy. Subjects
exclusion criteria included BMI > 30 upon admission to
study; CVD, Diabetes Mellitus (fasting blood sugar > 126
mg/dl), chronic inflammatory diseases (e.g. Crohn's,
rheumatoid arthritis), cancer in prior 5 years, renal or
hepatic disease, recent bacterial infection (< 2 weeks),
acute febrile illness in prior 2 months, history of drug or
alcohol abuse in prior 6 months, lipid-lowering, anti-
hypertensive or anti-inflammatory steroid medication
use, active weight loss > 5 kg in prior 3 months (intended
or unintended), concurrent or recent (within 30 days)
intervention study participation. The inclusion and exclu-
sion criteria were assessed via telephone screening, a
health history questionnaire, and the initial total choles-
terol screening visit. Subjects received oral and written
information about the study, including a comprehensive
study newsletter and individual written consent was
obtained from each subject.Nutrition Journal 2007, 6:6 http://www.nutritionj.com/content/6/1/6
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Subjects were asked to consume their usual diet with the
addition of either a placebo supplement or dietary fiber
from oat. The risks in the study were minimal. Subjects
maintained their usual activities during the study with
periodic visits for information sessions, sample collec-
tions, and supplement pickup.
Study design
The University of Minnesota Institutional Review Board
Human Subjects Committee approved all aspects of this
research. The study was a randomized, double-blind par-
allel group design. A total of 90 patients were enrolled
with 45 patients per treatment arm. Subjects were ran-
domly assigned to either placebo or treatment, stratified
by age and sex. Fifteen subjects (n = 10 treatment, n = 5
placebo) were excluded from final analysis because their
baseline cholesterol value was below 200 mg/dl despite a
screening value above 200 mg/dl. Treatment was 6 grams
of concentrated β-glucan from oat per day (from 12 g oat
bran concentrate containing 54% oat β glucan). Placebo
was 6 grams of dextrose monohydrate per day. Both were
delivered as dietary supplements in the form of a powder.
Subjects mixed their supplement with a beverage using a
study-provided electric hand blender (Braun). Subjects
were instructed to take the supplement via oral adminis-
tration with their morning and evening meal for six
weeks.
Study visits
Subjects attended an initial pre-screening visit to verify eli-
gibility for the study (visit 1). Subjects who met study cri-
teria were scheduled for a baseline visit, one day before
the intervention began (visit 2). Visits 3 and 4 were sched-
uled for day 21 (midpoint) and day 42 (final) of the inter-
vention.
Diet records
Three-day diet records were obtained from each subject at
the midpoint and final visits. Subjects recorded two week-
days and one weekend day of their total food intake. All
records were analyzed for total nutrient composition of
each day's intake using the First DataBank Nutritionist
Five software. Total calories, carbohydrate, fat, protein,
cholesterol, saturated fat, monounsaturated fat, polyun-
saturated fat, total fiber, soluble fiber, insoluble fiber and
crude fiber were analyzed for each subject for average
intake. Analysis of fiber did not include the addition of
oat β-glucan to the diet.
Blood samples
At each visit subjects were asked to fast overnight for a
minimum of 10 hours and then have blood samples
drawn at the General Clinical Research Center, University
of Minnesota, Twin Cities. Blood was drawn for the fol-
lowing measurements: plasma total cholesterol, triglycer-
ides, HDL cholesterol, LDL cholesterol, apolipoprotein A-
I, apolipoprotein B, complete blood count and differen-
tial, homocysteine, c-reactive protein and comprehensive
metabolic panel. Plasma LDL cholesterol concentration
was calculated using the Friedewald equation. All speci-
mens collected were transported via courier to Quest
Diagnostics (Wood Dale, IL) for analysis.
Anthropometric measurements
Blood pressure was measured at each visit for each subject
using a standardized sphygmomanometer (Tycos). Three
measurements were taken, one minute apart, with the
subject in a semi-reclined position following the
approved National Institutes of Health method [13].
These three values were averaged individually for diastolic
and systolic pressures. Standing weight was recorded every
visit to the nearest 1/4 lb with light clothing and no shoes
on a calibrated balance beam scale.
Symptom survey
Each visit participants completed a short survey rating gas-
trointestinal effects on a scale related to normal. Symp-
toms recorded include: frequency of stools, consistency of
stools, degree of intestinal bloating and degree of flatu-
lence.
Model intestinal fermentation
Concentrated oat β-glucan (54% β-glucan), partially
hydrolyzed guar gum (MW 400 kDa), and inulin (90% dp
= 10, 10% dp = 1–2) were subjected to model intestinal
fermentation [14]. Glucose served as a positive control
because it is fully fermentable by colonic bacteria. No
fiber was the negative control to assess the concentrations
of SCFA produced from substrates residing in the fecal
inoculum. Chemical reagents were obtained from Fisher
Scientific (New Hampton, NH, USA), Sigma Aldrich (St.
Louis, MO, USA), and VWR Scientific (West Chester, PA,
USA).
Briefly, the fibers were hydrated for 12 hours in 40 ml ster-
ile trypticase peptone media fortified with minerals, phos-
phate buffer, and a reducing solution (950 ml distilled
water, 6.25 g cysteine hydrochloride, 40 ml 1N NaOH,
6.25 g sodium sulfide monohydrate) at 4°C. Five-100 mL
serum bottles were prepared for each fiber sample (0.5 g),
one for each of the five time points: 0, 4, 8, 12, and 24
hours. Control bottles containing either 0.5 g glucose or
no added carbohydrate were prepared in the same man-
ner. Two hours prior to inoculation with fecal solution,
sample bottles were warmed to 37°C. Fecal inoculum was
prepared as described by McBurney and Thompson [14].
Fecal samples from three human subjects consuming a
nonspecified Western diet were pooled (125 g total) and
diluted with 400 ml distilled water. The solution wasNutrition Journal 2007, 6:6 http://www.nutritionj.com/content/6/1/6
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homogenized in a blender. Reducing solution was added
to the fecal ino 2 parts reducing solution [15].
Ten milliliters of fecal inoculum was added into each
serum bottle along with 0.8 mL Oxyrase® oxygen reducing
enzyme (Oxyrase Inc., Mansfield, OH). The bottles were
immediately flushed with carbon dioxide gas to eliminate
oxygen and generate anaerobic conditions. The bottles
were gently shaken in a 37°C water bath. One sample bot-
tle for each fiber was removed at 0, 4, 8, 12, and 24 hours.
Immediately upon removal, 1 mL of copper sulfate (200
g/L) was added to each bottle to kill the bacteria and cease
fermentation. Two-2 ml aliquots were removed. Samples
were prepared for gas chromatography as described previ-
ously [16,17].
Lactate, acetate, propionate, butyrate isobutyrate, 2-meth-
ylbutyrate, isovalerate, and valerate were determined by
gas chromatography using a Hewlett Packard 6890 gas
chromatograph (Hewlett Packard, Palo Alto, CA) with a
4% carbowax 20 M/80/120 carbopack B-DA column
(Supleco, Bellefonte, PA) a temperature of 175 degrees C.
Flow rates for nitrogen, hydrogen, and air were 24, 40,
and 450 mL/min, respectively. All SCFA concentrations
were corrected for the control concentration of SCFA at
each time point. Molar ratios of SCFA were determined by
dividing the number of moles of each SCFA (acetate, pro-
pionate, and butyrate) by the total moles of acetate, pro-
pionate, and butyrate.
Statistical analysis
Data was reported as means ± SEM. Changes were calcu-
lated by subtracting baseline from the 6-week value, so
that positive changes indicate an increase. Baseline values
and changes were compared between oat β-glucan and
control by two-sample t-tests, while paired t-tests were
used for within-group changes from baseline. In the
model intestinal fermentation, all SCFA concentrations
were corrected for the negative control concentration of
SCFA at each time point. SCFA concentrations were com-
pared between fibers at each time point separately, using
Tukey pairwise procedure for multiple comparisons. Sta-
tistical analyses were performed with SAS statistical soft-
ware package, versions 8.0 and 9.1 (SAS Institute Inc,
Cary, NC, USA).
Results
Human trial
Demographic and clinical characteristics of the oat β-glu-
can and control groups did not differ at baseline (Table 1).
There were no changes from baseline in dietary intake,
weight, or blood pressure in either group (Table 2). Total
cholesterol significantly decreased within the treatment
group (p < 0.025). Total cholesterol decreased 0.3 ± 0.1
mmol/L (mean ± SEM) in subjects consuming oat β-glu-
can. Total cholesterol did not significantly change within
the placebo group. Total cholesterol decreased 0.1 ± 0.08
mmol/L (mean ± SEM) within the placebo group, but this
change was not significant. Total cholesterol did not sig-
nificantly change between groups.
LDL cholesterol significantly decreased within the treat-
ment group (p < 0.025). LDL cholesterol dropped 0.3 ±
0.1 mmol/L (mean ± SEM) in subjects consuming oat β-
glucan. LDL cholesterol did not change significantly
within the placebo group; the mean decrease was 0.04
mmol/L. Treatment of oat β-glucan significantly lowered
LDL cholesterol compared to control (p < 0.026). HDL
cholesterol did not change significantly in either the treat-
ment or placebo group.
Triglycerides increased 0.09 ± 0.1 mmol/L (mean ± SEM)
in the treatment group, but this change was not signifi-
cantly different than 0. Triglycerides fell 0.2 ± 0.1 mmol/
L (mean ± SEM) in the placebo group. The triglyceride
change between the treatment and control group was sig-
nificantly different (p = 0.030).
The oat β-glucan group experienced significant reduction
from baseline in total cholesterol and LDL cholesterol,
and the reduction in LDL cholesterol was greater than in
the control group. Triglycerides were reduced in the con-
trol group but not the oat β-glucan group. Neither group
showed changes in HDL cholesterol, C-reactive protein,
homocysteine, insulin, or glucose.
Both groups reported no change in stool consistency,
stool frequency, and bloating during the study, although
the oat β-glucan group reported increased flatulence.
Three-day food records completed on days 1–3, 22–24,
and 39–41 were analyzed to verify dietary intake did not
significantly change during the study. Changes in energy
intake and diet composition are shown in Table 2.
Model intestinal fermentation
Concentrations of total short-chain fatty acids (TSCFA),
acetate, propionate, and butyrate produced during the
model intestinal fermentation are shown in Table 3. Con-
centrated oat β-glucan and inulin produced similar con-
centrations of TSCFA and were both significantly greater
than guar gum at 4 hours. Oat β-glucan TSCFA production
increased from 0 to 8 hours, and remained constant from
8 to 24 hours. Total short-chain fatty acid production by
inulin peaked at 8 hours and decreased until 24 hours.
Guar gum produced increasing concentrations of TSCFA
at all time points. At 24 hours, guar gum produced the
greatest concentrations of TSCFA while oat-β glucan and
inulin produced significantly few TSCFA.Nutrition Journal 2007, 6:6 http://www.nutritionj.com/content/6/1/6
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Acetate was the major contributor to TSCFA concentra-
tions at all time points by all fibers. Acetate production
mimicked the TSCFA production patterns with oat β-glu-
can and inulin being the fermented more rapidly than
guar gum between 0 and 4 hours. At 8 hours, inulin pro-
duced significantly more acetate than oat β-glucan and
guar gum. Acetate production at 12 hours was not differ-
ent between the three fibers. At 24 hours, oat β-glucan
produced the lowest concentrations of acetate, although
this difference was only significant between guar gum and
oat-β glucan.
Propionate was the SCFA produced in the second greatest
concentration by oat β-glucan and guar gum. Oat β-glu-
can produced little propionate between 0 and 8 hours.
From 8 to 24 hours, oat β-glucan produced propionate at
a constant rate. Concentrations of propionate produced
by oat β-glucan were less than guar gum but greater than
inulin from 8 to 24 hours.
Oat-β glucan produced the greatest butyrate concentra-
tions from 4 to 12 hours. Between 12 and 24 hours,
butyrate production by inulin increased dramatically,
resulting in the greatest butyrate production at 24 hours.
Oat β-glucan produced the second greatest concentration
Table 1: Baseline Demographic and Clinical Data
Treatment Placebo P value
n (female/male) 35 (22/13) 40 (28/12) 0.513
Age (yr) 44.5 ± 2.2 45.3 ± 2.0 0.796
Blood pressure (systolic/diastolic, 
mmHg)
121/69 ± 2.2/1.4 121.6/67.1 ± 1.9/1.5 0.868/0.760
Weight (kg) 81.8 ± 2.8 79.6 ± 2.9 0.598
Total Cholesterol (mmol/L) 6.2 ± 0.1 6.2 ± 0.1 0.976
Triglyceride (mmol/L)* 1.9 ± 0.1 1.9 ± 0.2 0.989
HDL cholesterol (mmol/L) 1.4 ± 0.06 1.3 ± 0.05 0.806
LDL cholesterol (mmol/L)** 4.1 ± 0.1 4.2 ± 0.1 0.651
Cholesterol/HDL ratio 4.8 ± 0.2 4.8 ± 0.2 0.981
C-Reactive protein (mg/dL) 0.35 ± 0.08 0.38 ± .06 0.817
Homocysteine (μmol/L) 8.0 ± 0.3 7.9 ± 0.3 0.861
Insulin (pmol/L) 56.2 ± 4.2 68.1 ± 9.0 0.273
Glucose (mmol/L) 5.4 ± 0.3 5.3 ± 0.1 0.840
Data are means ± SEM.
* Excludes one subject in the Placebo group with fasting triglycerides > 400 mg/dL.
** Excludes two subjects in the Placebo group with fasting triglycerides > 400 mg/dL
Table 2: Comparison of endpoints at six weeks expressed as changes from baseline.
Treatment Placebo P value
Total Cholesterol (mmol/L) -0.3 ± 0.1 *** -0.1 ± 0.08 0.184
LDL cholesterol (mmol/L)** -0.3 ± 0.1 *** -0.04 ± 0.08 0.026
HDL cholesterol (mmol/L) -0.02 ± 0.02 -0.009 ± 0.02 0.842
Triglyceride (mmol/L)* 0.09 ± 0.1 -0.2 ± 0.1*** 0.030
Cholesterol/HDL ratio -0.2 ± 0.1 -0.1 ± 0.1 0.947
C-Reactive protein (mg/dL) -0.03 ± 0.06 0.01 ± 0.04 0.546
Homocysteine (μM/L) 0.4 ± 0.4 0.2 ± 0.2 0.528
Insulin (pmol/L) 6.9 ± 4.9 4.2 ± 10.4 0.804
Glucose (mmol/L) 0.2 ± 0.09 0.03 ± 0.09 0.259
Weight (kg) -0.7 ± 0.3 1.4 ± 1.3 0.117
Blood pressure (systolic/diastolic, 
mmHg, value at end point)
119/69 ± 1.9/1.3 119/69 ± 2.0/1.7 0.832/0.856
Total Energy Intake per day (kJ) -519 ± 330 -343 ± 360 0.724
Carbohydrate intake (% of total) 0.4 ± 2.0 1.8 ± 1.3 0.535
Protein Intake (% of total) 0.9 ± 0.6 -0.9 ± 1.1 0.041
Fat Intake (% of total) -0.7 ± 1.8 -1.2 ± 1.1 0.784
Dietary Fiber Intake (grams) -0.3 ± 1.1 -1.4 ± 1.6 0.454
Data are means ± SEM.
***Statistically different from baseline, within group comparison p < 0.05Nutrition Journal 2007, 6:6 http://www.nutritionj.com/content/6/1/6
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of butyrate at 24 hours, with guar gum producing the least
butyrate.
Discussion
Large, prospective, epidemiologic studies find a protective
effect of dietary fiber against coronary heart disease and
form the basis for recommendations from the National
Academy of Science for fiber intake (38 and 25 grams per
day for young men and women)[18]. It has been pro-
posed that a protective effect of soluble dietary fiber
against CVD is mediated through direct or indirect effects
on serum lipids. This study supports that oat β-glucan's
role in CVD protection is through its effects on serum lip-
ids. Virtually all other markers tested, other than serum
lipids and apo B, did not significantly change as a result of
6 grams concentrated β-glucan.
Dietary fiber, as defined by the Institute of Medicine, con-
sists of nondigestible carbohydrates and lignin that are
intrinsic and intact in plants [19]. Functional fiber consists
of concentrated, nondigestible carbohydrates that have
beneficial physiological effects in humans [19]. The IOM
recommended the elimination of the terms soluble and
insoluble. New terms, viscous and fermentable, were recom-
mended to describe the physicochemical properties of fib-
ers. Viscous fibers such as β-glucan and guar gum have
been shown to decrease blood LDL-cholesterol concentra-
tions in animal models [20] and clinical intervention
studies [21]. We have shown that consumption of oat β-
glucan as a functional fiber has similar physiological
effects as oat β-glucan intact in oats.
The reduction of cholesterol is possibly a sum of several
effects. It is commonly accepted however that the majority
of effect is due to decreased absorption of bile acids. This
causes a removal of steroids from the body by fecal excre-
tion resulting in increased catabolism of cholesterol, an
increase in the secretion of bile acids, a decrease in lipo-
protein cholesterol secretion, and a reduction in the total
body pool of cholesterol [22]. Viscous fibers such as oat β-
glucan can interfere with the absorption of dietary fat and
cholesterol as well as enterohepatic recirculation of cho-
lesterol and bile acids.
Viscous fibers may also delay the gastric emptying of
ingested foods into the small intestine, resulting in a sen-
sation of fullness, which may help weight control.
Delayed gastric emptying may also reduce postprandial
Table 3: Total SCFA†, acetate, propionate, and butyrate production‡ (μmol/ml) of isolated oat β-glucan (54% soluble fiber), guar gum 
sample (MW 400 kDa) and inulin sample (degree of polymerization 100% ≈10) after 0, 4,8,12, and 24 hours in a model intestinal 
fermentation, analyzed by gas chromatography.
Sample Oat β-glucan Guar Gum Inulin
Total SCFA 0 h 0.6 ± 0.2 -0.7 ± 0.5 -0.3 ± 0.2
4 h 32.7 ± 0.3a*7 . 7  ±  0 . 0 2 b 33.8 ± 0.8a
8 h 50.5 ± 4.0a 45.7 ± 3.2a 75.4 ± 0.7b
12 h 50.3 ± 6.2 62.0 ± 0.6 55.6 ± 1.8
24 h 48.7 ± 1.5a 68.6 ± 0.8b 51.8 ± 0.8a
Acetate 0 h -0.4 ± 0.01 -0.2 ± 0.05 -0.2 ± 0.02
4 h 23.1 ± 0.9a 6.6 ± 0.5b 23.3 ± 0.4a
8 h 40.0 ± 3.1a 34.2 ± 2.2a 63.7 ± 1.8b
12 h 37.5 ± 4.5 45.5 ± 0.1 48.2 ± 4.2
24 h 24.7 ± 1.7a 34.6 ± 0.2b 30.3 ± 0.8ab
Propionate 0 h -0.1 ± 0.01 0.05 ± 0.04 -0.04 ± 0.01
4 h 0.7 ± 0.04 0.5 ± 0.1 0.4 ± 0.1
8 h 0.8 ± 0.7a 4.5 ± 0.8b -2.2 ± 0.1a
12 h 3.8 ± 1.2a 16.8 ± 0.3b -6.2 ± 0.2c
24 h 11.9 ± 0.004a 28.5 ± 0.7b 0.08 ± 0.1c
Butyrate 0 h -0.1 ± 0.02 -0.03 ± 0.04 -0.03 ± 0.02
4 h 0.4 ± 0.02 0.2 ± 0.05 0.2 ± 0.04
8 h 2.2 ± 0.3a 0.9 ± 0.2b 0.6 ± 0.05b
12 h 7.7 ± 0.9a 3.3 ± 0.1b -.004 ± 0.1c
24 h 13.3 ± 0.3a 6.8 ± 0.1b 23.1 ± 0.1c
† Total SCFA = acetate, propionate, butyrate, isobutyrate, 2-methylbutyrate, isovalerate, lactate, and valerate (if detectable).
‡Values shown are mean ± standard error, each from 2 samples
*Mean production of each compound was compared at each time point between oat β-glucan, guar gum, and inulin. Within each row, means that 
do not share a superscript letter are significantly different (p < 0.05), and means that share a letter are not significantly different.Nutrition Journal 2007, 6:6 http://www.nutritionj.com/content/6/1/6
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blood glucose concentrations leading to greater insulin
sensitivity. In this study however, subjects consuming oat
β-glucan or placebo had no change in weight. Perhaps a
six week study is too short to impact subjects' weight. In
addition, the oat β-glucan had no effect on fasting glucose
or insulin concentrations.
Dietary fiber intake may also displace saturated fat intake
and thus reduce CVD events [23]. However, three-day
food records show no significant difference in saturated
fat between treatment and placebo groups – supporting
the idea that dietary fiber has beneficial cardiovascular
effects independent of saturated fat.
The decrease in LDL cholesterol (0.3 mmol/L) as a result
of oat β-glucan administration was a modest decrease. Sta-
tin treatment has been shown to decrease LDL cholesterol
by 1.3 mmol/L over the course of a six week intervention
[24]. However, the decrease in LDL cholesterol as a result
of concentrated oat β-glucan administration is large
enough to be clinically relevant. A 0.26 mmol/L increase
in LDL cholesterol results in a 12% increase in risk of CVD
[25].
Dietary interventions, such as The Portfolio diet which is
high in plant sterols, soy protein, almonds, and viscous
fiber, have been documented to reduce cholesterol levels
as effectively as statin therapy [26]. The 12 gram dose of
oat β-glucan used in this study was an acceptable dose to
the subjects and provided clinically significant changes in
cholesterol levels. The effectiveness of concentrated oat β-
glucan as an add-on to statin therapy is beyond the scope
of this study, but should be considered for future research.
Concentrated oat β-glucan would be suitable as a stand-
alone supplement to lower cholesterol. This product
could also be used as a food ingredient to increase fiber
content of food. When incorporated into minimally proc-
essed, low-fat food, concentrated oat β-glucan is hypothe-
sized to retain is hypocholesterolemic effects.
This study also estimated the fermentability of concen-
trated oat β-glucan in a model intestinal fermentation sys-
tem. Studying colonic fermentation in healthy humans is
very difficult. The colonic epithelium is a dynamic system
which is continually absorbing SCFAs as they are being
produced by colonic bacteria. Currently, no method exists
to measure SCFA absorption across the epithelium in
humans. Short-chain fatty acid concentration in feces is a
reasonable measurement of colonic fermentability. How-
ever, model intestinal fermentation is a more rapid, non-
invasive, method of assessing fermentability and results
from this method correspond with fermentability in vivo
[27,28].
Colonic fermentation varies between individuals as a
result of species of gut bacteria and intestinal transit time.
Absorption varies between individuals due to colonic
retention time and other metabolites present in the feces,
such as bicarbonate or sodium. The batch fermentation
system eliminates differences in SCFA production due to
the aforementioned variables and allows several fibers to
be compared subjectively. Short-chain fatty acid produc-
tion may play a role in decreasing cholesterol, but acetate
and propionate concentrations were not remarkably dif-
ferent than concentrations produced by inulin or guar
gum. Other mechanisms discussed above likely contrib-
ute to the cholesterol lowering feature of oat β-glucan.
The data from this study supports numerous studies
showing increased intakes of viscous fiber decrease blood
LDL-cholesterol concentrations [21]. Insulin concentra-
tions, glucose concentrations, weight, homocysteine and
CRP however did not significantly change in response to
oat β-glucan and lead us to the question "Is this functional
fiber different than dietary fiber?" It is likely that some
food constituents, such as vitamins, trace elements, phe-
nolic compounds, and phytoestrogens, found in fiber-rich
foods also affect CVD risk and operate via pathways other
than the lipid-regulating pathway [29]. The functional
fiber, oat β-glucan, may be beneficial to subjects with high
CVD risk because of its ability to significantly lower LDL
cholesterol concentrations. However, several other mech-
anisms may underlie the cardiovascular benefits of dietary
fiber. These include improvement in postprandial glucose
and insulin responses and lowering of blood pressure and
body weight [30]. Thus, the present study suggests that oat
β-glucan significantly lowers LDL-cholesterol concentra-
tions in subjects with high CVD risk.
Conclusion
A dosage of 6 grams concentrated β-glucan per day for six
weeks produced significant reduction from baseline in
total and LDL cholesterol. The reduction in LDL choles-
terol was significantly greater than in the control group.
These results indicate that concentrated β-glucan may be
beneficial to high cardiovascular disease risk populations.
Concentrated oat β-glucan is a fermentable fiber, with
SCFA production similar to inulin and guar gum, as
shown in model intestinal fermentation. This source of
fiber will likely increase SCFA concentrations in the
human colon, in addition to lowering LDL cholesterol.
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